Alnylam Pharmaceuticals, Inc. reported its financial results for the quarter ended September 30, 2026, filing an 8-K on October 29, 2026. The company reported total revenues of $1,458 million for the third quarter of 2026, representing a 17% increase compared to the same period in 2025.
Net product revenues for the quarter were $1,292 million, a 52% increase year-over-year. This growth was primarily driven by the TTR franchise, which generated $1,150 million in net product revenues. Specifically, AMVUTTRA (vutrisiran) generated $1,130 million, while ONPATTRO (patisiran) generated $20 million. Total Rare net product revenues, from GIVLAARI (givosiran) and OXLUMO (lumasiran), totaled $142 million.
Research and development expenses for the three months ended September 30, 2026, were $409 million, an increase of 14% compared to the prior year. The company also reported GAAP net income of $2,167 million and non-GAAP net income of $2,242 million.
In pipeline news, Alnylam announced an expansion of the target enrollment for the TRITON-CM Phase 3 study of nucresiran to approximately 2,250 patients. The company stated it expects to launch nucresiran in ATTR-CM by 2030, assuming positive data and regulatory approval. Additionally, the company presented positive Phase 1 data for brezosiran (ALN-HTT02) in Huntington's disease, demonstrating robust target engagement. Alnylam plans to initiate a pivotal study for brezosiran in 2027.
